Clinical trial phase IV, prospective, non-randomized, for the evaluation of myocardial dysfunction early predictor of clinically significant cardiac damage induced by Herceptin in women with HER2 positive breast cancer (adjuvant and metastatic setting) and its correlation with markers organic heart damage, chronic inflammation and oxidative stress.

Trial Profile

Clinical trial phase IV, prospective, non-randomized, for the evaluation of myocardial dysfunction early predictor of clinically significant cardiac damage induced by Herceptin in women with HER2 positive breast cancer (adjuvant and metastatic setting) and its correlation with markers organic heart damage, chronic inflammation and oxidative stress.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2012

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top